J&J partner Aspen, with no orders for its COVID shot, warns low demand sends 'bad message'

Late last year, Johnson & Johnson’s COVID production partner Aspen Pharmacare touted the game-changing potential of its “monumental” licensing deal to make and sell J&J’s single-dose shot in Africa. Five months later, and two months after Aspen started production, the effort has encountered a problem currently familiar to all pandemic vaccine manufacturers.